DK2844292T3 - ST2L-antagonister og fremgangsmåder til anvendelse - Google Patents

ST2L-antagonister og fremgangsmåder til anvendelse

Info

Publication number
DK2844292T3
DK2844292T3 DK13785158.0T DK13785158T DK2844292T3 DK 2844292 T3 DK2844292 T3 DK 2844292T3 DK 13785158 T DK13785158 T DK 13785158T DK 2844292 T3 DK2844292 T3 DK 2844292T3
Authority
DK
Denmark
Prior art keywords
methods
st2l antagonists
st2l
antagonists
Prior art date
Application number
DK13785158.0T
Other languages
English (en)
Inventor
Karen Duffy
Catherine Healy
Roberta Lamb
Ravi Malaviya
Michael Pratta
Natalie Fursov
Jinquan Luo
Michael Naso
Mark Tornetta
John Wheeler
Sheng-Jiun Wu
Leroy Hall
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of DK2844292T3 publication Critical patent/DK2844292T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
DK13785158.0T 2012-04-30 2013-04-29 ST2L-antagonister og fremgangsmåder til anvendelse DK2844292T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261640238P 2012-04-30 2012-04-30
US201261640407P 2012-04-30 2012-04-30
US13/798,226 US9212227B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
US13/798,204 US9090694B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists
PCT/US2013/038637 WO2013165894A2 (en) 2012-04-30 2013-04-29 St2l antagonists and methods of use

Publications (1)

Publication Number Publication Date
DK2844292T3 true DK2844292T3 (da) 2019-10-21

Family

ID=49477497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13785158.0T DK2844292T3 (da) 2012-04-30 2013-04-29 ST2L-antagonister og fremgangsmåder til anvendelse

Country Status (37)

Country Link
US (4) US9090694B2 (da)
EP (2) EP2844292B1 (da)
JP (3) JP6283354B2 (da)
KR (2) KR102147140B1 (da)
CN (2) CN104411333B (da)
AR (1) AR090909A1 (da)
AU (2) AU2013256645B2 (da)
BR (1) BR112014027165A2 (da)
CA (1) CA2871948C (da)
CL (1) CL2014002955A1 (da)
CO (1) CO7240389A2 (da)
CR (1) CR20140488A (da)
CY (1) CY1122308T1 (da)
DK (1) DK2844292T3 (da)
EA (2) EA031047B1 (da)
EC (1) ECSP14025178A (da)
ES (1) ES2755094T3 (da)
HK (1) HK1208182A1 (da)
HR (1) HRP20191884T1 (da)
HU (1) HUE045864T2 (da)
IL (2) IL235401B (da)
LT (1) LT2844292T (da)
MX (2) MX358134B (da)
MY (1) MY166062A (da)
NI (1) NI201400125A (da)
NZ (3) NZ740221A (da)
PE (1) PE20150641A1 (da)
PH (2) PH12014502435A1 (da)
PL (1) PL2844292T3 (da)
PT (1) PT2844292T (da)
RS (1) RS59511B1 (da)
SG (2) SG10201608525SA (da)
SI (1) SI2844292T1 (da)
TW (3) TWI700299B (da)
UA (1) UA118336C2 (da)
UY (1) UY34774A (da)
WO (1) WO2013165894A2 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP3141260B1 (en) * 2009-11-30 2019-08-14 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2014152195A1 (en) 2013-03-15 2014-09-25 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
KR102446386B1 (ko) 2014-01-10 2022-09-22 아납티스바이오, 아이엔씨. 인터루킨-33 (il-33)에 대한 항체
EP3134120B1 (en) 2014-04-21 2024-01-24 The Children's Hospital of Philadelphia Compositions and methods for treating cytokine-related disorders
EP3157634B1 (en) 2014-06-23 2018-12-12 Bionomics, Inc. Antibodies that bind lgr4
WO2016077366A1 (en) 2014-11-10 2016-05-19 Genentec, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
EP3218403B1 (en) 2014-11-10 2020-05-13 F.Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
US20180036404A1 (en) * 2015-03-02 2018-02-08 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
WO2016207304A2 (en) * 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
JP2019508382A (ja) * 2016-01-14 2019-03-28 アナプティスバイオ インコーポレイティッド Ｉｌ−３３阻害剤を使用したアレルギー反応の阻害
US20190225682A1 (en) * 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
US20190202907A1 (en) * 2016-09-02 2019-07-04 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MY197534A (en) 2017-02-10 2023-06-21 Genentech Inc Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018190990A1 (en) 2017-04-13 2018-10-18 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CA3226165A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
US20210403579A1 (en) * 2018-10-31 2021-12-30 Delinia, Inc. Multivalent regulatory t cell modulators
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
JP2023501316A (ja) 2019-11-04 2023-01-18 メドイミューン・リミテッド 腎機能障害を治療するための抗ｉｌ－３３治療薬
CA3158323A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
CR20220461A (es) 2020-03-13 2022-10-21 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
BR112022019937A2 (pt) 2020-04-06 2022-12-13 Medimmune Ltd Tratamento de síndrome do desconforto respiratório agudo com antagonistas de ligação de eixo de il-33
JP2023525826A (ja) 2020-05-12 2023-06-19 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｓｔ２抗原結合タンパク質
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
AR125753A1 (es) * 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023160610A1 (en) * 2022-02-24 2023-08-31 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
DE69738806D1 (de) 1996-10-10 2008-08-14 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CA2587627A1 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
TWI454480B (zh) 2006-08-18 2014-10-01 Novartis Ag 催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CA2686683A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8817596B2 (en) 2009-01-09 2014-08-26 Futurewei Technologies, Inc. Protecting ingress and egress of a label switched path
US7879978B2 (en) * 2009-03-31 2011-02-01 Centocor Ortho Biotech, Inc. Macaca fascicularis ST2L
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP3141260B1 (en) 2009-11-30 2019-08-14 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
PE20130192A1 (es) 2010-03-30 2013-02-27 Centocor Ortho Biotech Inc Anticuerpos il-25 humanizados
PL2556090T3 (pl) 2010-04-09 2017-07-31 Critical Care Diagnostics, Inc. Rozpuszczalne ludzkie przeciwciała st-2 i metody analityczne ich oznaczania
NZ701825A (en) 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
WO2012047583A2 (en) 2010-09-27 2012-04-12 Janssen Biotech, Inc. Antibodies binding human collagen ii
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
TW201238976A (en) 2011-02-23 2012-10-01 Hoffmann La Roche Antibodies against human IL33R and uses thereof
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2

Also Published As

Publication number Publication date
CN104411333A (zh) 2015-03-11
PH12014502435A1 (en) 2015-01-12
SG11201407028WA (en) 2015-01-29
IL235401B (en) 2020-10-29
PT2844292T (pt) 2019-11-26
US20130336980A1 (en) 2013-12-19
KR20200037886A (ko) 2020-04-09
EP2844292A2 (en) 2015-03-11
TW201730216A (zh) 2017-09-01
PL2844292T3 (pl) 2020-03-31
TW201345923A (zh) 2013-11-16
CN107098973A (zh) 2017-08-29
NZ740221A (en) 2019-11-29
TWI687440B (zh) 2020-03-11
ECSP14025178A (es) 2015-08-31
MX358134B (es) 2018-08-06
PH12018501839A1 (en) 2020-09-14
EA201891264A3 (ru) 2019-02-28
BR112014027165A2 (pt) 2017-07-18
NI201400125A (es) 2016-11-30
AR090909A1 (es) 2014-12-17
CN104411333B (zh) 2017-04-26
EA031047B1 (ru) 2018-11-30
AU2017202610A1 (en) 2017-05-11
EP2844292A4 (en) 2016-05-25
US20170066831A1 (en) 2017-03-09
TW202019969A (zh) 2020-06-01
CR20140488A (es) 2015-01-12
WO2013165894A2 (en) 2013-11-07
NZ702136A (en) 2017-03-31
AU2013256645B2 (en) 2017-06-08
US20190062439A1 (en) 2019-02-28
JP2019162136A (ja) 2019-09-26
HUE045864T2 (hu) 2020-01-28
CA2871948A1 (en) 2013-11-07
ES2755094T3 (es) 2020-04-21
US10450377B2 (en) 2019-10-22
IL254569A0 (en) 2017-11-30
HK1208182A1 (en) 2016-02-26
IL254569B (en) 2020-10-29
TWI700299B (zh) 2020-08-01
PE20150641A1 (es) 2015-05-11
US9951137B2 (en) 2018-04-24
KR20150008152A (ko) 2015-01-21
JP2015516817A (ja) 2015-06-18
CY1122308T1 (el) 2021-01-27
EA201891264A2 (ru) 2018-11-30
CO7240389A2 (es) 2015-04-17
EP3597219A1 (en) 2020-01-22
UY34774A (es) 2013-11-29
MY166062A (en) 2018-05-22
MX2014013200A (es) 2014-12-08
AU2017202610B2 (en) 2019-06-13
CA2871948C (en) 2020-09-08
UA118336C2 (uk) 2019-01-10
SG10201608525SA (en) 2016-12-29
JP6622274B2 (ja) 2019-12-18
EP2844292B1 (en) 2019-08-21
SI2844292T1 (sl) 2020-02-28
EA201491996A1 (ru) 2015-04-30
LT2844292T (lt) 2019-11-25
WO2013165894A3 (en) 2014-03-27
HRP20191884T1 (hr) 2020-02-07
RS59511B1 (sr) 2019-12-31
JP6283354B2 (ja) 2018-02-21
KR102147140B1 (ko) 2020-08-25
AU2017202610B9 (en) 2019-06-20
MX2018009430A (es) 2020-09-02
US9212227B2 (en) 2015-12-15
AU2013256645A1 (en) 2014-11-13
CL2014002955A1 (es) 2015-01-16
JP2018064560A (ja) 2018-04-26
IL235401A0 (en) 2014-12-31
US20130287777A1 (en) 2013-10-31
US9090694B2 (en) 2015-07-28
TWI589588B (zh) 2017-07-01
NZ729913A (en) 2018-07-27

Similar Documents

Publication Publication Date Title
DK2844292T3 (da) ST2L-antagonister og fremgangsmåder til anvendelse
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK3087095T3 (da) FcRn-antagonist og fremgangsmåder til anvendelse
DK2815066T3 (da) Selektivt korroderbart borehulsartikel og fremgangsmåde til anvendelse
DK2850202T3 (da) Fremgangsmåder og grupper
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK2928533T3 (da) Medicinske slanger og fremgangsmåder til fremstilling
PT2909204T (pt) Inibidores de gsk3 e métodos de utilização dos mesmos
BR112015007125A2 (pt) aparelho e método
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
PT2852461T (pt) Dispositivos de rede capilar e métodos de utilização
DK3930322T3 (da) Fremgangsmåder og anordninger til kodning
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2841684T3 (da) Oliefeltanordning og fremgangsmåde til anvendelse
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
DK2854822T3 (da) Polysaccharidsammensætninger og fremgangsmåder til anvendelse
DK2909181T3 (da) PKM2-modulatorer og fremgangsmåder til anvendelse deraf
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
DK2827883T3 (da) Tfpi-inhibitorer og fremgangsmåder til anvendelse
DK3211410T3 (da) Elektrode og anvendelse deraf